The evolving study of early-onset depression

Child and Adolescent Psychiatric Clinics of North America

Volumn 9, Issue 1, 2000, Pages 135-157

  Martin, A ^a   Kaufman, J ^a   Charney, D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ALGORITHM; CHILD; CHILD PSYCHIATRY; CLINICAL RESEARCH; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; ADOLESCENT; ADULT; BRAIN; CLINICAL TRIAL; DRUG EFFECT; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALGORITHMS; ANTIDEPRESSIVE AGENTS; BRAIN; CHILD; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0033628926     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1056-4993(18)30139-1     Document Type: Review

References (129)

1. Ambrosini P.J. Wagner K.D. Biederman J. Multicenter open-label sertraline study in adolescent outpatients with major depression J Am Acad Child Adolesc Psychiatry 38 1999 566 572
2. American Academy of Child and Adolescent Psychiatry: Practice parameters for the assessment and treatment of children and adolescents with depressive disorders J Am Acad Child Adolesc Psychiatry 37 10 1998 63 83
3. Angold A. Costello E.J. Worthman C.M. Puberty and depression: The roles of age, pubertal status and pubertal timing Psychol Med 28 1998 51 61
4. Apter A. Ratzoni G. King R.A. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression J Am Acad Child Adolesc Psychiatry 33 1994 342 348
5. Arato M. Banki C.M. Bissette G. Elevated CSF CRF in suicide victims Biol Psychiatry 25 1989 355 359
6. Arborelius L. Owens M.J. Plotsky P.M. The role of corticotropin-releasing factor in depression and anxiety disorders J Endocrinol 160 1999 1 12
7. Arredondo D.E. Bupropion treatment of adolescent depression. Scientific Proceed-ings of the 146th Annual Meeting of the American Psychiatric Association 1993 American Psychiatric Association San Francisco, California
8. Birmaher B. Ryan N.D. Williamson D.E. Childhood and adolescent depression: A review of the past 10 years. Part I [see comments] J Am Acad Child Adolesc Psychiatry 35 1996 1427 1439
9. Birmaher B. Ryan N.D. Williamson D.E. Childhood and adolescent depression: A review of the past 10 years. Part II [see comments] J Am Acad Child Adolesc Psychiatry 35 1996 1575 1583
10. Botteron K.N. Vannier M.W. Geller B. Preliminary study of magnetic resonance imaging characteristics in 8- to 16-year-olds with mania J Am Acad Child Adolesc Psychiatry 34 1995 742 749
11. Bremner J.D. Innis R.B. Salomon R.I.V.L. Positron emission tomography measure-ment of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse Arch Gen Psychiatry 54 1997 364 374
12. Bremner J.D. Randall P. Scott T.M. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder [see com-ments] Am J Psychiatry 152 1995 973 981
13. Brent D.A. Holder D. Kolko D. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy Arch Gen Psychia-try 54 1997 877 885
14. Cameron H.A. Tanapat P. Gould E. Adrenal steroids and N-methyl-D-aspartate recep-tor activation regulate neurogenesis in the dentate gyrus of adult rats through a common pathway Neuroscience 82 1998 349 354
15. Christie K.A. Burke J.D. Jr Regier D.A. Epidemiologic evidence for early onset of mental disorders and higher risk of drug abuse in young adults Am J Psychiatry 145 1988 971 975
16. Conners C.K. Casat C.D. Gualtieri C.T. Bupropion hydrochloride in attention deficit disorder with hyperactivity J Am Acad Child Adolesc Psychiatry 35 1996 1314 1321
17. CopIan J.D. Andrews M.W. Rosenblum L.A. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: Implications for the pathophysiology of mood and anxiety disorders Proc Natl Acad Sci U S A 93 1996 1619 1623
18. Cosgrove P.V.F. Fluvoxamine in the treatment of depressive illness in children and adolescents J Psychopharmacol 8 1994 118
19. Daly J.M. Wilens T. The use of tricyclic antidepressants in children and adolescents Pediatr Clin North Am 45 1998 1123 1135
20. Davis R. Whittington R. Bryson H.M. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression [see comments] Drugs 53 1997 608 636
21. De Bettis M.D. Gold P.V.V. Geracioti T.D. Jr Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression Am J Psychiatry 150 1993 656 657
22. Drevets W.C. Price J.L. Simpson J.R. Jr Subgenual prefrontal cortex abnormalities in mood disorders [see comments] Nature 386 1997 824 827
23. Duman R.S. Charney D.S. Cell atrophy and loss in major depression [editorial] [in process citation] Biol Psychiatry 45 1999 1083 1084
24. Duman R.S. Henirtger G.R. Nestler E.J. A molecular and cellular theory of depression [see comments] Arch Gen Psychiatry 54 1997 597 606
25. Emslie C.J. Rush A.L. Weinberg W.A. Fluoxetine in child and adolescent depres-sion: Acute and maintenance treatment Depress Anxiety 7 1998 32 39
26. Emslie G.J. Rush A.L. Weinberg W.A. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression Arch Gen Psychiatry 54 1997 1031 1037
27. Feigin A. Kurlan R. McDermott M.P. A controlled trial of deprenyl in children with Tourette’s syndrome and attention deficit hyperactivity disorder Neurology 46 1996 965 968
28. Findling R. Magnus R.D. Preskorn S.H. Open pharmacokinetic study of nefazo-done in children and adolescents with depression. In Scientific Proceedings of the 44th Annual Meeting of the American Academy of Child and Adolescent Psychiatry 1997 American Academy of Child and Adolescent Psychiatry Toronto, Ontario
29. Findling R.L. Schwartz M.A. Flannery D.J. Venlafaxine in adults with attention-deficit / hyperactivity disorder: An open clinical trial [see comments] J Chin Psychia-try 57 1996 184 189
30. Geller B. Cooper T.B. Graham D.L. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder J Am Acad Child Adolesc Psychiatry 31 1992 34 44
31. Geller B. Fox L.W. Clark K.A. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children [see comments] J Am Acad Child Adolesc Psychiatry 33 1994 461 468
32. Geller B. Fox L.W. Fletcher M. Effect of tricydic antidepressants on switching to mania and on the onset of bipolarity in depressed 6- to 12-year-olds J Am Acad Child Adolesc Psychiatry 32 1993 43 50
33. Geller B. Reising D. Leonard H.L. Critical review of tricyclic antidepressant use in children and adolescents J Am Acad Child Adolesc Psychiatry 38 1999 513 516
34. Goldman-Rakic P.S. Brown R.M. Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys Brain Res 256 1982 339 349
35. Guidotti A. Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 44 1998 865 873
36. Gutgesell H. Atkins D. Barst R. AHA scientific statement: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs [in process citation] J Am Acad Child Adolesc Psychiatry 38 1999 1047 1050
37. Hamilton M. A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
38. Harrington R. Fudge H. Rutter M. Adult outcomes of childhood and adolescent depression. I. Psychiatric status Arch Gen Psychiatry 47 1990 465 473
39. Harrington R. Rutter M. Weissman M. Psychiatric disorders in the relatives of depressed probands. I. Comparison of prepubertal, adolescent and early adult onset cases J Affect Disord 42 1997 9 22
40. Hazell P. O’Connell D. Heathcote D. Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis [see comments] BMJ 310 1995 897 901
41. Hilton S.E. Maradit H. Moller H.J. Serotonin syndrome and drug combinations: Focus on MAOI and RIMA Eur Arch Psychiatry Clin Neurosci 247 1997 113 119
42. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety J Psychiatr Res 33 1999 181 214
43. Jensen P.S. Bhatara V.S. Vitiello B. Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice J Am Acad Child Adolesc Psychiatry 38 1999 557 565
44. Jobson K.O. Potter W.Z. International Psychopharmacology Algorithm Project Report Psychopharmacol Bull 31 1995 457 500
45. Kashani J.H. McGee R.O. Clarkson S.E. Depression in a sample of 9-year-old children. Prevalence and associated characteristics Arch Gen Psychiatry 40 1983 1217 1223
46. Kaufman J. Birmaher B. Brent D. Schedule for Affective Disorders and Schizo-phrenia for School-Aged Children—Present and Lifetime Version (K-SADS-PL): Ini-tial reliability and validity data J Am Acad Child Adolesc Psychiatry 36 1997 980 988
47. Kaufman J. Birmaher B. Perel J. The corticotropirt-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children Biol Psy-chiatry 42 1997 669 679
48. Kaufman J, Martin A, King RA, et al: Are child-, adolescent-, and adult-onset depression one and the same disorder? Am J Psychiatry, submitted
49. Kaufman J. Ryan N. The Neurobiology of Child and Adolescent Mood Disorders Charney D.S. Nestler E.J. Bunney B.J. Neurobiology of Mental Illness 1999 Oxford University Press New York 810 822
50. Keller M.B. Ryan N.D. Birmaher B. Paroxetine and imipramine in the treatment of adolescent depression. In Program and Abstracts on New Research from the 151st Annual Meeting of the American Psychiatric Association 1998 American Psychiatric Association Toronto, Ontario
51. Kessler R.C. Walters E.E. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Sur-vey Depress Anxiety 7 1998 3 14
52. Klein R.G. Mannuzza S. Koplewicz H.S. Adolescent depression: Controlled desipramine treatment and atypical features Depress Anxiety 7 1998 15 31
53. Kovacs M. Devlin B. Internalizing disorders in childhood J Child Psychol Psychiatry 39 1998 47 63
54. Kovacs M. Feinberg T.L. Crouse-Novak M. Depressive disorders in childhood II. A longitudinal study of the risk for a subsequent major depression Arch Gen Psychiatry 41 1984 643 649
55. Kovacs M. Feinberg T.L. Crouse-Novak M.A. Depressive disorders in childhood I. A longitudinal prospective study of characteristics and recovery Arch Gen Psychi-atry 41 1984 229 237
56. Kovacs M. Goldston D. Gatsonis C. Suicidal behaviors and childhood-onset de-pressive disorders: A longitudinal investigation J Am Acad Child Adolesc Psychia-try 32 1993 8 20
57. Kovacs M. Krol R.S. Voti L. Early onset psychopathology and the risk for teenage pregnancy among clinically referred girls J Am Acad Child Adolesc Psychiatry 33 1994 106 113
58. Kramer A.D. Feiguine R.J. Clinical effects of amitriptyline in adolescent depression A pilot study J Am Acad Child Psychiatry 20 1981 636 644
59. Kramer M.S. Cutler N. Feighner J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors [see comments] Science 281 1998 1640 1645
60. Kutcher S. Boulos C. Ward B. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial J Am Acad Child Adolesc Psychia-try 33 1994 686 694
61. Kye C. Ryan N. Pharmacologic treatment of child and adolescent depression Child Adolesc Psychiatr Clin North Am 4 1995 261 281
62. Kye C.H. Waterman G.S. Ryan N.D. A randomized, controlled trial of amitripty-line in the acute treatment of adolescent major depression J Am Acad Child Adolesc Psychiatry 35 1996 1139 1144
63. Labellarte M.J. Walkup J.T. Riddle M.A. The new antidepressants Selective serotonin reuptake inhibitors Pediatr Chin North Am 45 1998 1137 1155
64. Ladd C.O. Owens M.J. Nemeroff C.B. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation Endocrinology 137 1996 1212 1218
65. Lewinsohn P.M. Clarke G.N. Seeley J.R. Major depression in community adoles-cents: Age at onset, episode duration, and time to recurrence [see comments] J Am Acad Child Adolesc Psychiatry 33 1994 809 818
66. Liebowitz M.R. Schneier F. Gitow A. Reversible monoamine oxidase-A inhibi-tors in social phobia Clin Neuropharmacol 16 2 1993 S83 88
67. Mandoki M.W. Tapia M.R. Tapia M.A. Venlafaxine in the treatment of children and adolescents with major depression Psychopharmacol Bull 33 1997 149 154
68. Mann J.J. Aarons S.F. Wilner P.J. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor Arch Gen Psychiatry 46 1989 45 50
69. March J.S. Biederman J. Wolkow R. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial [see comments] JAMA 280 1998 1752 1756
70. Massana J. Moller H.J. Burrows G.D. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder Int Clin Psychopharmacol 14 1999 73 80
71. McConville B.J. Mirmery K.L. Sorter M.T. An open study of the effects of sertralirte on adolescent major depression J Child Adolesc Psychopharmacol 6 1996 41 51
72. Montgomery S.A. Chairman’s overview. The place of reboxetine in antidepressant therapy J Clin Psychiatry 59 14 1998 26 29
73. Mufson L. Weissman M.M. Moreau D. Efficacy of interpersonal psychotherapy for depressed adolescents Arch Gen Psychiatry 56 1999 573 579
74. Nemeroff C.B. Bissette G. Akil H. Neuropeptide concentrations in the cerebro-spinal fluid of depressed patients treated with electroconvulsive therapy. Cortico-trophin-releasing factor, beta-endorphin and somatostatin Br J Psychiatry 158 1991 59 63
75. Nemeroff C.B. Owens M.J. Bissette G. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims Arch Gen Psychiatry 45 1988 577 579
76. Nemeroff C.B. Widerloy E. Bissette G. Elevated concentrations of CSF corticotro-pin-releasing factor-like immunoreactivity in depressed patients Science 226 1984 1342 1344
77. Nolen W.A. Haffmans P.M. Bouvy P.F. Monoamine oxidase inhibitors in resistant major depression A double-blind comparison of brofaromine and tranylcypromirte in patients resistant to tricyclic antidepressants J Affect Disord 28 1993 189 197
78. Nutt D. Substance-P antagonists: A new treatment for depression? Lancet 352 1998 1644 1666
79. Oesterheld J.R. Flockhart D.A. Cytochrome P450-mediated drug interactions Child Adolesc Psychiatr Clin North Am 9 2000 43 76
80. Olfson M. Marcus S.C. Pincus H.A. Antidepressant prescribing practices of outpatient psychiatrists Arch Gen Psychiatry 55 1998 310 316
81. Olvera R.L. Pliszka S.R. Luh J. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents J Child Adolesc Psychopharmacol 6 1996 241 250
82. Petty F. GABA and mood disorders: A brief review and hypothesis J Affect Disord 34 1995 275 281
83. Petty F. Trivedi M.H. Fulton M. Benzodiazepines as antidepressants: Does GABA play a role in depression? Biol Psychiatry 38 1995 578 591
84. Plotsky PM, Thrivikraman KV, Cladji C, et al: The effects of neonatal rearing environment on CRF mRNA and CRF receptor levels in adult rat brain. J Neurosci, in press
85. Post R.M. Gold P. Rubinow D.R. Peptides in the cerebrospinal fluid of neuropsy-chiatric patients: An approach to central nervous system peptide function Life Sci 31 1982 1 15
86. Priest R.G. Recent clinical development with reversible and selective amine oxidase inhibitors: A valuable addition to the armamentarium. Chairman’s introduction [published erratum appears in J Clin Psychopharmacol 15:398, 1995] J Clin Psycho-pharmacol 15 Suppl 2 1995 1 3
87. Prosser J. Hughes C.W. Sheikha S. Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders: A preliminary study J Child Adolesc Psychopharmacol 7 1997 181 199
88. Puig-Antich J. Goetz D. Davies M. A controlled family history study of prepubertal major depressive disorder Arch Gen Psychiatry 46 1989 406 418
89. Puig-Antich J. Perel J.M. Lupatkin W. Imipramine in prepubertal major de-pressive disorders Arch Gen Psychiatry 44 1987 81 89
90. Puig-Antich J. Weston B. The diagnosis and treatment of major depressive disorder in childhood Annu Rev Med 34 1983 231 245
91. Rajkowska G. Miguel-Hidalgo J.J. Wei J. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression [in process citation] Biol Psychiatry 45 1999 1085 1098
92. Rao U. Ryan N.D. Birmaher B. Unipolar depression in adolescents: Clinical outcome in adulthood J Am Acad Child Adolesc Psychiatry 34 1995 566 578
93. Reinecke M.A. Ryan N.E. DuBois D.L. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: A review and meta-analysis [see comments] J Am Acad Child Adolesc Psychiatry 37 1998 26 34
94. Rey J.M. Walter G. Half a century of ECT use in young people Am J Psychiatry 154 1997 595 602
95. Riddle MA, Claghorn J, Gaffney G, et al: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A controlled multicenter trial. In Scientific Proceedings of the 43d Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Philadelphia, Pennsylvania, 1996
96. Rie H.E. Depression in childhood. A survey of some pertinent contributions J Am Acad Child Psychiatry 5 1966 653 685
97. Riggs P.D. Leon S.L. Mikulich S.K. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder J Am Acad Child Adolesc Psychiatry 37 1998 1271 1278
98. Romeo E. Strohle A. Spalletta G. Effects of antidepressant treatment on neuroactive steroids in major depression Am J Psychiatry 155 1998 910 913
99. Rosenberg D.R. Lewis D.A. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: A tyrosine hydroxylase immunohistochemical analysis J Comp Neurol 358 1995 383 400
100. Rosenblum L.A. Paully G.S. The effects of varying environmental demands on mater-nal and infant behavior Child Dev 55 1984 305 314
101. Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids J Psychiatr Res 31 1997 297 314
102. Rutter M. Hersov L. Child Psychiatry 1977 Blackwell Press London
103. Ryan N.D. Puig-Antich J. Ambrosini P. The clinical picture of major depression in children and adolescents Arch Gen Psychiatry 44 1987 854 861
104. Ryan N.D. Puig-Antich J. Rabinovich H. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants [published erratum appears in J Am Acad Child Adolesc Psychiatry 28:144, 1989] J Am Acad Child Adolesc Psychiatry 27 1988 755 758
105. Sanacora G, Mason CF, Rothman DL, et al: Reduced cortical GABA levels in depressed patients determined by ’H-MRS magnetic resonance spectroscopy. In Scientific Proceedings of the 28th Annual Meeting of the Society for Neuroscience. Los Angeles, California, Society for Neuroscience, 1998
106. Shaffer D. Gould M.S. Fisher P. Psychiatric diagnosis in child and adolescent suicide Arch Gen Psychiatry 53 1996 339 348
107. Sheline Y.I. Wang P.W. Gado M.H. Hippocampal atrophy in recurrent major depression Proc Natl Acad Sci USA 93 1996 3908 3913
108. Shirayama Y. Mitsushio H. Takashirna M. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat Brain Res 739 1996 70 78
109. Spencer T. Biederman J. Wilens T. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder Am J Psychiatry 155 1998 693 695
110. Stahl S.M. Peptides and psychiatry, Part 3: Substance P and serendipity: Novel psychotropics are a possibility J Clin Psychiatry 60 1999 140 141
111. Sternbach H. The serotonin syndrome [see comments] Am J Psychiatry 148 1991 705 713
112. Stimmel G.L. Dopheide J.A. Stahl S.M. Mirtazapine: An antidepressant with noradren-ergic and specific serotonergic effects Pharrnacotherapy 17 1997 10 21
113. Stoll A.L. Mayer P.V. Kolbrener M. Antidepressant-associated mania: A con-trolled comparison with spontaneous mania Am J Psychiatry 151 1994 1642 1645
114. Strober M. Lampert C. Schmidt S. The course of major depressive disorder in adolescents: I. Recovery and risk of manic switching in a follow-up of psychotic and nonpsychotic subtypes J Am Acad Child Adolesc Psychiatry 32 1993 34 42
115. Strohle A. Romeo E. Hermann B. Concentrations of 3 alpha-reduced neuroac-tive steroids and their precursors in plasma of patients with major depression and after clinical recovery Biol Psychiatry 45 1999 274 277
116. Sundstrom I. Andersson A. Nyberg S. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects Neuroendocrinology 67 1998 126 138
117. Sundstrom I. Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: An open trial Psychoneuroendocrinology 23 1998 73 88
118. Tanapat P. Galea L.A. Gould E. Stress inhibits the proliferation of granule cell precursors in the developing dentate gyrus Int J Dev Neurosci 16 1998 235 239
119. Thomsen P.H. Child and adolescent obsessive-compulsive disorder treated with citalopram: Findings from an open trial of 23 cases J Child Adolesc Psychopharma-col 7 1997 157 166
120. Tierney E. Joshi P.T. Linas J.F. Sertraline for major depression in children and adolescents: Preliminary clinical experience J Child Adolesc Psychopharmacol 5 1995 13 27
121. Uzunov D.P. Cooper T.B. Costa E. Fluoxetine-elicited changes in brain neuroster-oid content measured by negative ion mass fragmentography Proc Natl Acad Sci USA 93 1996 12599 12604
122. Uzunova V. Sheline Y. Davis J.M. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxe-tine or fluvoxamine Proc Natl Acad Sci USA 95 1998 3239 3244
123. Vale W. Spiess J. Rivier C. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin Science 213 1981 1394 1397
124. Walter G. Koster K. Rey J.M. Electroconvulsive therapy in adolescents: Experience, knowledge, and attitudes of recipients J Am Acad Child Adolesc Psychiatry 38 1999 594 599
125. Walter G. Rey J.M. Mitchell P.B. Practitioner review: Electroconvulsive therapy in adolescents J Child Psychol Psychiatry 40 1999 325 334
126. Wang M. Seippel L. Purdy R.H. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregrtenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hy-droxy-5 alpha-pregnart-20-one J Chin Endocrinol Metab 81 1996 1076 1082
127. Werry J.S. Biederman J. Thisted R. Resolved: Cardiac arrhythmias make desipra-mine an unacceptable choice in children J Am Acad Child Adolesc Psychiatry 34 1995 1239 1245
128. Wheatley D.P. van Moffaert M. Timmerman L. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group J Clin Psychiatry 59 1998 306 312
129. Zarate C.A. Jr Tohen M. Baraibar G. Prescribing trends of antidepressants in bipolar depression J Chin Psychiatry 56 1995 260 264